Special report: cardiovascular pharmacogenomics
BlueCross BlueShield Association
Record ID 32010000202
English
Authors' objectives:
This Special Report will survey the literature in the field of pharmacogenomics in relation to cardiovascular disease. It will highlight the particular diseases and drugs that have been studied in this field, and point out any promising areas. Areas not addressed in this Report include cytochrome P450 testing for warfarin dosage adjustment and use of genetic testing for cardiovascular disease susceptibility or outcome.
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/contact-tec.html
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Adrenergic beta-Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Cardiovascular Diseases
- Cardiovascular System
- Diuretics
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Pharmacogenetics
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.